Investor Presentaiton

Key Takeaways Discovery CMC (Manufacturing & Quality) Clinical Development Innovent 信达生物制药 Commercialization 用目 Growing into a global biopharmaceutical company with fully-integrated capabilities (discovery, development, manufacturing, commercialization) and clear strategy of global innovation Robust pipeline of 25 diverse-staged assets (5 commercialized, 1 NDA under NMPA review, 5 pivotal trials, 14 at clinical stage) Driving upside potentials of prioritized assets with global rights (CD47 cluster, LAG-3 cluster, TIGIT cluster, OXM31, VEGF/c-protein) Building world-class R&D platform in global territory, Innovent Academy as a powerful discovery engine focusing on novel targets and cutting- edge technologies Committed to develop truly innovative products (potentially global First-in-Class and Best-in-class blockbuster drugs) Partner-of-choice for comprehensive global collaborations (in-license, out-license, assets, technology platform) Leverage the advantages of China clinical development to accelerate pipeline's global development and registration Note: 1: We own rights of OXM3 in Greater China. Innovent Confidential Copyright©2021 Innovent Biologics 46 46

View entire presentation